Cancer Imaging With Radiopharmaceuticals
Cancer Imaging with Radiopharmaceuticals
The National Cancer Institute (NCI), an agency within the federal National Institutes of Health, in July awarded MU a $10 million grant to create a new Center for Single Photon-Emitting Cancer Imaging Agents.
The award is one of the largest research grants ever received by MU through a peer-reviewed, competitive government funding process. It will allow researchers at MU and the Harry S Truman Memorial Veterans Hospital to pioneer new, innovative methods of cancer detection and treatment.
The grant strengthens a formal agreement between MU and the Truman Memorial Veterans Administration Hospital to build a premiere cancer-imaging center. The center will be housed in the 9,000-square-foot radiopharmaceuticals laboratory located on the lowest level of the new outpatient center at the hospital.
"I am very pleased that the initial $4 million investment that I secured allowed MU to win this $10 million cancer research contract," said Sen. Bond. "This announcement underscores that MU is increasingly capable of competing for and winning front-line, big-dollar research contracts."
Radiopharmaceuticals are radioactive drugs that help doctors detect, diagnose and treat diseases. Doctors inject molecules "labeled" with radioisotopes into patients, where the molecular structure of the drug allows it to "target" specific tissues. Once the radioactive material reaches its target -- whether the heart, liver, brain or a tumor -- specialized instruments are used to produce an image that helps physicians make more informed diagnoses.